The European First Episode Schizophrenia Trial (EUFEST): Comparison of outcome in The European study of the effectiveness of haloperidol, amisulpride . The study helps solve the question of which category of antipsychotic medications best address impaired cognition, which affects a significant. The EUFEST study then undertook with a pragmatic open randomized-controlled trial design to compare the effectiveness of second-generation antipsychotic.

Author: Nataur Dole
Country: South Africa
Language: English (Spanish)
Genre: Science
Published (Last): 27 February 2006
Pages: 404
PDF File Size: 1.68 Mb
ePub File Size: 5.70 Mb
ISBN: 225-3-90834-921-4
Downloads: 76932
Price: Free* [*Free Regsitration Required]
Uploader: Mikazuru

SchizophreniaSchizophreniform disorderSchizoaffective disorder. The Lancet ; Study information Scientific title The European study of the effectiveness of haloperidol, amisulpride, olanzapine, quetiapine, and ziprasidone on loss of retention in first episode schizophrenia Acronym EUFEST Study hypothesis What is the effectiveness of low doses of haloperidol and regular doses of amisulpride, olanzapine, quetiapine, and ziprasidone on loss of one year retention in patients with recent onset of schizophrenia, schizoaffective, and schizophreniform disorder?

Ethics approval Ethics approval received from the local medical ethics committee Study design Multicentre, randomised active controlled, parallel group trial Primary study design Interventional Secondary study design Randomised controlled trial Trial setting Hospitals Trial type Treatment Patient information sheet Condition Schizophrenia, schizophreniform, or schizoaffective disorder Intervention Drug: Analysis was by intention to treat. Comparisons with haloperidol showed lower risks for any-cause discontinuation with amisulpride hazard ratio [HR] 0.

Secondary outcome measures At regular time intervals patients are followed-up until 12 months after recruitment: The presence of one or more of the contra-indications against any of the study drugs.

  IEC 60097 PDF

Patients and their treating physicians were not blinded to the assigned treatment.

These and other facts have stimulated discussions regarding the effectiveness of the new generation of antipsychotics.

The primary outcome measure was all-cause treatment discontinuation. Intolerance to one of the drugs in this study; 4.

The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial.

This outcome is assessed at regular time intervals until 12 months after recruitment. Plain English Summary Not provided at time of registration Trial website http: Result of results found for within. Genetic determinants of response to antipsychotic drugs 9. Quality of life 6. The aim of the European First Episode Schizophrenia Trial EUFEST is to compare treatment with amisulpride, quetiapine, olanzapine and ziprasidone to a low dose of haloperidol in an unselected sample of first episode schizophrenia patients with minimal prior exposure to antipsychotics.

Retention to allocated study drug, which is the time that the patient stays on the randomised drug within the study dose range. Intolerance to one of the drugs in eifest study 4.

At present, more than patients have been recruited and randomized in the following countries: Secondary measures include changes in different dimensions of psychopathology, side effects, compliance, social needs, quality of life, substance abuse and cognitive functions. Side effects – extrapyramidal symptoms EPS side-effect profile, sexual side effects and weight gain 3. PfizerAstraZenecaSanofi-Aventis. Psychopathology – positive symptoms, negative symptoms, depression, agitation-excitement, disorganisation 2.


Multicentre, randomised active controlled, parallel group trial. This effort represents the first independently designed trans-European schizophrenia treatment trial.

Diagnosis of schizophrenia; 2. Natural history of schizophrenia.

The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial.

The primary outcome measure is retention in treatment, defined as time to discontinuation of study drug. Such studies were usually conducted in highly selected samples, and were generally designed and financed by the manufacturer of the drug tested. However, we cannot conclude that second-generation drugs are more efficacious than is haloperidol, since discontinuation rates are not necessarily consistent with symptomatic improvement.

Comparison of outcome studh first episode schizophrenia with different low dose antipsychotic drug regimens.

We focus on the real world treatment of first episode patients by enrolling heterogeneous patient populations, including patients who show comorbid drug abuse or who are aggressive or suicidal or less likely to be compliant with treatment. Home Who are we? EUFEST assesses the effectiveness of a low dose of haloperidol versus regular doses of 4 second generation antipsychotics: The study should be finished by the end of and it is expected that results will yield relevant clinical information with regard to the effectiveness of the second generation antipsychotics.